Genentech stock surges as new drugs deliver big revenue

Wall Street was cheering Genentech's high-priced roster of biotech meds, bidding up the biotech giant's stock price after it announced a whopping 73 percent increase in quarterly profits. Operating revenue jumped 35 percent to $1.5 billion for the three months ended June 30. Genentech Chairman and CEO Arthur Levinson told analysts that the company is in an "exciting phase of transformation and growth," with a string of positive clinical trials behind it and a slate of nine FDA applications ahead.

- read this story from the San Francisco Chronicle for more

Suggested Articles

Biotech leaders criticized the dismissals of Chinese scientists from U.S. universities in a letter with more than 150 signatures.

In this week's EuroBiotech Report, Merck allies with Themis on vaccine R&D, Juvenescence raises $100 million and GSK files for anemia approval. 

In our EuroBiotech roundup this week, Scancell withdraws IND, Oxurion’s eye drug fails phase 2a and Abivax starts ulcerative colitis trial.